Milestone Pharmaceuticals (NASDAQ:MIST) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Milestone Pharmaceuticals (NASDAQ:MIST) from a hold rating to a sell rating in a research report report published on Saturday.

MIST has been the subject of several other research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a research report on Monday, December 1st. Wells Fargo & Company began coverage on shares of Milestone Pharmaceuticals in a research report on Thursday, September 11th. They set an “overweight” rating and a $4.00 price target for the company. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $6.67.

Milestone Pharmaceuticals Trading Down 2.5%

Shares of Milestone Pharmaceuticals stock opened at $2.35 on Friday. Milestone Pharmaceuticals has a fifty-two week low of $0.63 and a fifty-two week high of $3.06. The business’s fifty day moving average is $2.18 and its two-hundred day moving average is $1.92. The company has a quick ratio of 8.24, a current ratio of 8.24 and a debt-to-equity ratio of 2.74. The firm has a market cap of $200.15 million, a PE ratio of -2.87 and a beta of 0.41.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.05. Analysts anticipate that Milestone Pharmaceuticals will post -0.62 earnings per share for the current year.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Sapient Capital LLC bought a new position in Milestone Pharmaceuticals in the third quarter worth about $25,000. Bay Rivers Group acquired a new stake in shares of Milestone Pharmaceuticals during the 2nd quarter worth approximately $28,000. Bank of America Corp DE lifted its holdings in shares of Milestone Pharmaceuticals by 200,550.0% in the 3rd quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock worth $32,000 after purchasing an additional 16,044 shares during the last quarter. Stephenson & Company Inc. acquired a new position in Milestone Pharmaceuticals during the 3rd quarter valued at approximately $40,000. Finally, Creative Planning grew its stake in Milestone Pharmaceuticals by 74.6% during the 2nd quarter. Creative Planning now owns 23,410 shares of the company’s stock worth $45,000 after buying an additional 10,000 shares during the last quarter. Institutional investors and hedge funds own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.